13.06.2025

Submission of an application in the ABM competition: Proacta develops the i-COPE project in the field of cardio-oncology

The Management Board of Proacta SA announces that on June 11, 2025, a consortium agreement was signed between Proacta SA, Jan Długosz University in Częstochowa (consortium leader), and the Provincial Specialist Hospital of the Blessed Virgin Mary in Częstochowa.

On the basis of the agreement, on June 13 this year, a joint application was submitted for co-financing of a research and development project as part of the Medical Research Agency's competition entitled “TRANSMED I – development of R&D projects in the field of translational medicine”.

Project title:

Integrated cardio-oncology platform for the assessment and prediction of cardiotoxicity in oncology patients – i-COPE

Total project cost: PLN 11,425,816.00

Requested funding amount: PLN 10,797,316.00

The project aims to develop a breakthrough solution using artificial intelligence (AI) and advanced machine learning (ML) models to monitor the risk of cardiovascular complications in patients treated for breast cancer.

The aim of the project is to create an online clinical platform that integrates:

• clinical,
• laboratory,
• imaging (including DICOM format),
• oncological, and molecular data.

The resulting tool will enable physicians to quickly and automatically analyze the risk of cardiac complications. As a result, it will be possible to individualize patient care and reduce the risk of discontinuing cancer therapy. The platform will take the form of an interactive risk panel (CDSS), available online and supporting medical decisions.

Proacta SA's role in the project:

Proacta's role is crucial. The company is responsible for:

• designing and building the database,
• implementing AI models,
• providing server infrastructure,
• supporting DevOps/MLOps teams, database specialists, and bioinformaticians.

Proacta's experience in medical data analysis, bioinformatics, and the implementation of medtech solutions will enable the effective implementation of the project's ambitious goals. i-COPE complements the company's existing portfolio of digital health solutions, including the Dbam o Siebie Smart LAB platform currently under development.

The project is currently awaiting the results of a formal and substantive evaluation by the Medical Research Agency.